Amgen Inc. is experiencing a positive shift in market sentiment, gaining traction amidst recent industry developments.
Amgen Inc. (NASDAQ:AMGN) is rising today, with shares up 1.07% to close at CA$383.85. This uptick comes in the wake of heightened investor interest following recent news regarding the competitive landscape for cholesterol-lowering drugs.
Investor takeaway: Despite the challenges posed by Novartis' recent trial failure, Amgen's pipeline remains robust, with potential for significant upside if their cholesterol drug olpasiran proves effective in upcoming trials.
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$203.47B
P/E
23.3x
Div. yield
2.61%
Div. / share
$9.80
52W high
$447.03
52W low
$262.49
1W change
-3.81%
Beta
0.43
Analyst Price Targets
Based on 32 analysts covering AMGN · as of Sep 17, 2026
Wall Street analysts forecast AMGN stock price to rise 1297.3% over the next 12 months.
Consensus
Buy3.63 / 5.00
Avg. Target
C$388.03
+1297.3% Upside
Current Price
C$27.77
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
38.0%
Annualized
90-Day Vol
33.1%
Annualized
Trend (90d)
+40.3%
Annualized drift
90d Mean
C$438.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$398.47 | C$349.55 – C$454.23 |
| 60 trading days | C$418.07 | C$347.38 – C$503.16 |
| 90 trading days | C$438.65 | C$349.61 – C$550.36 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Amgen's Market Cap Reaches $205.32 Billion
With a P/E ratio of 23.37 and a profit margin of 22.95%, Amgen's financial health supports ongoing investment despite the recent challenges in the cholesterol drug market.
Bull case
Analysts believe that Amgen's olpasiran could succeed where Novartis' pelacarsen failed, as it has shown stronger Lp(a) reductions in earlier studies. The company is testing its drugs in specific patient populations, which may lead to better outcomes than Novartis' disappointing results.
Bear case
The failure of Novartis' trial raises concerns about the efficacy of Amgen's olpasiran due to similarities in trial design. If Amgen cannot show that lowering Lp(a) leads to fewer cardiovascular events, it may face significant scrutiny and valuation challenges.
Market Reaction to Novartis' Trial Failure
Advertisement
Amgen's stock gain today is partly due to the recent failure of Novartis' cholesterol drug pelacarsen, which did not reduce cardiovascular events despite lowering Lp(a) levels. This has raised the stakes for Amgen, as investors are now more focused on the potential success of olpasiran in upcoming trials.
Amgen's Strong Financial Position
With a market cap of $205.32 billion and a profit margin of 22.95%, Amgen is well-positioned to weather the storm caused by recent industry setbacks. The company's P/E ratio of 23.37 reflects a solid valuation, indicating that investors still see long-term potential in its drug pipeline.
Looking Ahead: Upcoming Trials and Investor Sentiment
Amgen's upcoming trials for olpasiran will be crucial in determining its future trajectory. Investors are keenly awaiting results that could either validate or challenge the company's position in the cholesterol drug market. The sentiment surrounding Amgen remains cautiously optimistic as it navigates these challenges.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
